Posted by Michael Wonder on 05 Jun 2023
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make Yusimry, a Humira biosimilar, available to patients
1 June 2023 - YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and shipping fees.
Mark Cuban Cost Plus Drug Company and Coherus BioSciences today announced plans to offer Mark Cuban Cost Plus Drug Company customers Yusimry (adalimumab-aqvh), a biosimilar of Humira (adalimumab injection), in July 2023.
